Bio Green Med Solution

Bio Green Med Solution ROCE

The Return on Capital Employed (ROCE) of Bio Green Med Solution (BGMS) as of Nov 4, 2026 is -123.17 %. In the previous year, Return on Capital Employed (ROCE) was 552.16 % — a change of -122.31% (lower).

ROCE

-123.17 %

YoY

-122.31%

Last updated:

In 2025, Bio Green Med Solution's return on capital employed (ROCE) was -123.17 %, a -122.31% increase from the 552.16 % ROCE in the previous year.

The Bio Green Med Solution ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-62.52 USD
Jan 1, 2019
-82.77 USD
Jan 1, 2020
-31.98 USD
Jan 1, 2021
-59.40 USD
Jan 1, 2022
-135.35 USD
Jan 1, 2023
-4,193.25 USD
Jan 1, 2024
552.16 USD
Jan 1, 2025
-123.17 USD
The Bio Green Med Solution ROCE history
YEARROCEYoY
-123.17 %-122.31%
552.16 %-113.17%
-4,193.25 %+2,998.08%
-135.35 %+127.87%
-59.40 %+85.74%
-31.98 %-61.37%
-82.77 %+32.40%
-62.52 %+43.38%
-43.60 %-56.02%
-99.14 %+15.48%
-85.85 %-17.02%
-103.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Green Med Solution Stock analysis

What does Bio Green Med Solution do? Cyclacel Pharmaceuticals, Inc. generates revenue through its clinical stage biopharmaceutical products, focusing on anticancer drugs that target the cell cycle. The company's product portfolio includes sapacitabine, a nucleoside analog for oral administration, seliciclib as a CDK inhibitor, and CYC065, a second-generation CDK inhibitor. These drugs are developed for hematological malignancies and solid tumors, with sapacitabine and seliciclib being key candidates in their pipeline. The company sells its products to healthcare providers and pharmaceutical distributors in the oncology sector. The firm's lead candidate, sapacitabine, is positioned as an alternative to conventional chemotherapies like gemcitabine and cytarabine (Ara-C), which are generic drugs already in use. Seliciclib, an oral CDK2/9 inhibitor, and CYC065, targeting CDK2/9 enzymes, are marketed for their utility in treating various cancers. The company's revenue streams are derived from clinical development partnerships and potential future commercialization of these drugs once approved. Cyclacel's business model centers on developing and advancing its drug candidates through clinical trials, with the goal of securing regulatory approvals and partnering with larger pharmaceutical companies for distribution. The company does not yet have commercial products on the market, so its current revenue comes from research grants and potential licensing agreements. The primary customer segments are oncology specialists and pharmaceutical distributors specializing in cancer treatments. Bio Green Med Solution is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Bio Green Med Solution's Return on Capital Employed (ROCE)

Bio Green Med Solution's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Bio Green Med Solution's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Bio Green Med Solution's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Bio Green Med Solution’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Bio Green Med Solution stock

Return on Capital Employed (ROCE) of Bio Green Med Solution is -123.17 % in 2025.

Return on Capital Employed (ROCE) of Bio Green Med Solution changed from 552.16 % to -123.17 %, representing a -122.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Bio Green Med Solution since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Bio Green Med Solution with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio Green Med Solution

All Key Metrics — Bio Green Med Solution